* 1. drug allergy. * 2. intolerance to lactose and / or cow's milk proteins. * 3. renal failure with gfr \<30 ml / min. * 4. liver cirrhosis or severe liver failure * 5. pregnancy or breastfeeding. * 6. blood dyscrasias or cardiac disorders that in the opinion of the investigator contraindicate the use of colchicine. * 7. pre-existing degenerative neuromuscular disease. * 8. acute or chronic diarrhea or malabsorptive syndrome that in the judgment of the clinician contraindicates the use of colchicine. * 9. crp\> 80 mg / l or ferritin\> 3 times lan * 10. shock or hemodynamic instability. * 11. respiratory distress measured by pao2 / fio2 \<300 or baseline o2 saturation ≤ 93%. * 12. patients undergoing mechanical ventilation. * 13. chronic treatment with any drug that, in the opinion of the investigator, interacts with colchicine and cannot be discontinued during the clinical trial, unacceptably increasing the risk of toxicity (digoxin, cyclosporine, etc.) * 14. have received any dose of colchicine, tocilizumab, any antil6 or antil1 drug. * 15. current treatment with corticosteroids (except chronic corticosteroid therapy without recent increase in dose). * 16. participation in any other clinical trial of patients with covid-19. * 17. any other condition that, in the opinion of the investigator, contraindicates the use of colchicine or puts the subject at risk due to their participation in the study.

* 1. drug allergy. * 2. intolerance to lactose and / or cow's milk proteins. * 3. renal failure with gfr \<30 ml / min. * 4. liver cirrhosis or severe liver failure * 5. pregnancy or breastfeeding. * 6. blood dyscrasias or cardiac disorders that in the opinion of the investigator contraindicate the use of colchicine. * 7. pre-existing degenerative neuromuscular disease. * 8. acute or chronic diarrhea or malabsorptive syndrome that in the judgment of the clinician contraindicates the use of colchicine. * 9. crp\> 80 mg / l or ferritin\> 3 times lan * 10. shock or hemodynamic instability. * 11. respiratory distress measured by pao2 / fio2 \<300 or baseline o2 saturation ≤ 93%. * 12. patients undergoing mechanical ventilation. * 13. chronic treatment with any drug that, in the opinion of the investigator, interacts with colchicine and cannot be discontinued during the clinical trial, unacceptably increasing the risk of toxicity (digoxin, cyclosporine, etc.) * 14. have received any dose of colchicine, tocilizumab, any antil6 or antil1 drug. * 15. current treatment with corticosteroids (except chronic corticosteroid therapy without recent increase in dose). * 16. participation in any other clinical trial of patients with covid-19. * 17. any other condition that, in the opinion of the investigator, contraindicates the use of colchicine or puts the subject at risk due to their participation in the study.

- 1. drug allergy. - 2. intolerance to lactose and / or cow's milk proteins. - 3. renal failure with gfr <30 ml / min. - 4. liver cirrhosis or severe liver failure - 5. pregnancy or breastfeeding. - 6. blood dyscrasias or cardiac disorders that in the opinion of the investigator contraindicate the use of colchicine. - 7. pre-existing degenerative neuromuscular disease. - 8. acute or chronic diarrhea or malabsorptive syndrome that in the judgment of the clinician contraindicates the use of colchicine. - 9. crp> 80 mg / l or ferritin> 3 times lan - 10. shock or hemodynamic instability. - 11. respiratory distress measured by pao2 / fio2 <300 or baseline o2 saturation ≤ 93%. - 12. patients undergoing mechanical ventilation. - 13. chronic treatment with any drug that, in the opinion of the investigator, interacts with colchicine and cannot be discontinued during the clinical trial, unacceptably increasing the risk of toxicity (digoxin, cyclosporine, etc.) - 14. have received any dose of colchicine, tocilizumab, any antil6 or antil1 drug. - 15. current treatment with corticosteroids (except chronic corticosteroid therapy without recent increase in dose). - 16. participation in any other clinical trial of patients with covid-19. - 17. any other condition that, in the opinion of the investigator, contraindicates the use of colchicine or puts the subject at risk due to their participation in the study.

- 1. drug allergy. - 2. intolerance to lactose and / or cow's milk proteins. - 3. renal failure with gfr <30 ml / min. - 4. liver cirrhosis or severe liver failure - 5. pregnancy or breastfeeding. - 6. blood dyscrasias or cardiac disorders that in the opinion of the investigator contraindicate the use of colchicine. - 7. pre-existing degenerative neuromuscular disease. - 8. acute or chronic diarrhea or malabsorptive syndrome that in the judgment of the clinician contraindicates the use of colchicine. - 9. crp> 80 mg / l or ferritin> 3 times lan - 10. shock or hemodynamic instability. - 11. respiratory distress measured by pao2 / fio2 <300 or baseline o2 saturation ≤ 93%. - 12. patients undergoing mechanical ventilation. - 13. chronic treatment with any drug that, in the opinion of the investigator, interacts with colchicine and cannot be discontinued during the clinical trial, unacceptably increasing the risk of toxicity (digoxin, cyclosporine, etc.) - 14. have received any dose of colchicine, tocilizumab, any antil6 or antil1 drug. - 15. current treatment with corticosteroids (except chronic corticosteroid therapy without recent increase in dose). - 16. participation in any other clinical trial of patients with covid-19. - 17. any other condition that, in the opinion of the investigator, contraindicates the use of colchicine or puts the subject at risk due to their participation in the study.